記住我
Patients with chronic lymphocytic leukaemia (CLL) typically receive first-line chemoimmunotherapy comprising the anti-CD20 antibody rituximab plus either fludarabine and cyclophosphamide or bendamustine for patients ≤65 or >65 years of age, respectively. In the past decade, several agents have been approved for this malignancy, including the BTK inhibitor ibrutinib, the BCL2 antagonist venetoclax and the novel anti-CD20 antibody obinutuzumab; however, data from multi-arm comparative trials of these agents are limited. Now, results from the phase III GAIA–CLL13 trial support the use of venetoclax–obinutuzumab with or without ibrutinib in this setting.
留言 (0)